United States clinical practice guidelines for metastatic colorectal cancer recommend use of medications impacted by genetic variants but do not recommend testing. We analyzed real-world treatment using a cancer registry and claims dataset to explore pharmacogenomic (PGx) medication treatment patterns and characterize exposure. In a cohort of 6957 patients, most (86.9%) were exposed to at least one chemotherapy medication with PGx guidelines. In a cohort of 2223 patients with retail pharmacy claims available, most (79.2%) were treated with at least one non-chemotherapy (79.2%) medication with PGx guidelines. PGx-associated chemotherapy exposure was associated with age, race/ethnicity, educational attainment, and rurality. PGx-associated non-chemotherapy exposure was associated with medication use and comorbidities. The potential impact of PGx testing is large and policies aimed at increasing PGx testing at diagnosis may impact treatment decisions for patients with metastatic colorectal cancer as most patients are exposed to medications with pharmacogenomics implications during treatment.
Bibliographical noteFunding Information:
ZTR received support through National Institutes of Health’s National Center for Advancing Translational Sciences, grants TL1R002493 and UL1TR002494 for his work on this project. JFF, PAJ, KMK, and DLS report no conflicts or funding for this work. HMP was funded by NIH P30 CA77598 Masonic Cancer Center.
© 2022, The Author(s), under exclusive licence to Springer Nature Limited.
PubMed: MeSH publication types
- Journal Article